{"id":11725,"date":"2015-06-19T10:03:42","date_gmt":"2015-06-19T14:03:42","guid":{"rendered":"http:\/\/revivogen.globalprint.ca\/?page_id=11725"},"modified":"2016-11-16T22:19:52","modified_gmt":"2016-11-17T03:19:52","slug":"publications","status":"publish","type":"page","link":"https:\/\/revivogen.ca\/md\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

PUBLICATIONS<\/h1><\/span>
<\/div><\/div><\/div>

GAMMA LINOLENIC ACID, ALPHA LINOLENIC ACID, AND LINOLEIC ACID<\/span><\/strong><\/h2><\/div>

In the following studies, Gamma Linolenic Acid (GLA), Alpha Linolenic Acid (ALA), and Linoleic Acid were shown to be the most potent known inhibitors of type 1 and 2 forms of 5-alpha reductase and highly effective in decreasing the levels of dihydrotestosterone (DHT), when applied topically. More importantly this is accomplished without affecting any systemic effects.\u00a0The study further suggests that these fatty acids can be useful in the treatment of disorders related to dihydrotestosterone including male pattern hair loss, acne, and excessive female body hair (hirsuitism).<\/p>\n<\/div>

<\/div><\/div><\/div>

<\/i><\/i><\/span>Study A - Growth suppression of hamster flank organs by topical application of gamma-linolenic and other fatty acid inhibitors of 5 alpha-reductase.<\/span><\/a><\/h4><\/div>
STUDY A<\/strong>
\nGrowth suppression of hamster flank organs by topical application of gamma-linolenic and other fatty acid inhibitors of 5 alpha-reductase.<\/p>\n

AUTHOR<\/strong>
\nLiang T; Liao S<\/p>\n

JOURNAL<\/strong>
\nJournal of Investigational Dermatology: 1997 Aug; 109 (2): 152-7<\/p>\n

ABSTRACT<\/strong>
\nCertain unsaturated aliphatic fatty acids, such as gamma-linolenic acid, inhibit 5alpha-reductase activity in vitro and in vivo. Hamster flank organ growth, as measured by the increase in the area of pigmented macule, is dependent on androgen. When one of the paired flank organs of a castrated hamster was treated topically with testosterone, the treated organ, but not the contralateral flank organ, became larger and darker. Topical application of gamma-linolenic acid to the testosterone-treated flank organ suppressed this testosterone effect. Other fatty acids that were not inhibitors of 5alpha-reductases were not active. Topical treatment of hamster flank organs with 5alpha-dihydrotestosterone also stimulated the growth of the organ. This 5alpha-dihydrotestosterone-dependent activity, however, was not significantly affected by gamma-linolenic acid, suggesting that flank organ growth was dependent on 5alpha-dihydrotestosterone and that gamma-linolenic acid acted by inhibiting 5alpha-reductase. With intact male hamsters, the endogenous androgen-dependent growth of flank organs is also suppressed by topical treatment with gamma-linolenic acid. The effect of gamma-linolenic acid is localized at the site of its application; topical application of gamma-linolenic acid did not affect the androgen-dependent growth of other organs such as testis, epididymis, seminal vesicle, and prostate. gamma-Linolenic acid, with low toxicity and absence of systemic effect, therefore may be potentially useful for treatment of androgen-dependent skin disorders.<\/div><\/div><\/div>

<\/i><\/i><\/span>Study B - Androgen action: molecular mechanism and medical application.<\/span><\/a><\/h4><\/div>
STUDY B<\/strong>
\nAndrogen action: molecular mechanism and medical application.<\/p>\n

AUTHOR<\/strong>
\nLiao S<\/p>\n

JOURNAL<\/strong>
\nJournal of Formos Medical Association: 1994 Sep; 93 (9): 741-51<\/p>\n

ABSTRACT<\/strong>
\nAndrogen action in many organs, such as prostate and skin, is dependent on the conversion of testosterone by 5 alpha-reductase to 5 alpha-dihydrotestosterone. 5 alpha-Dihydrotestosterone then binds to the androgen receptor to regulate specific gene expression. Inhibitors of 5 alpha-reductase are useful for the selective treatment of prostatic cancer, benign prostate hyperplasia, acne, baldness and female hirsuitism, without affecting spermatogenesis, sexual behavior and smooth muscle growth, that do not require the conversion of testosterone to 5 alpha-dihydrotestosterone. Certain unsaturated fatty acids, such as gamma-linolenic acid, are potent 5 alpha-reductase inhibitors, suggesting a linkage between unsaturated fatty acids and androgen action. Mutations in androgen receptor genes are responsible for many cases of androgen-insensitivity. In some prostate cancer cells, some antiandrogens may act like androgens in stimulating the proliferation of the cancer cells because these antiandrogens can bind to a mutated androgen receptor and transactivate target genes. Prostate cancers are usually androgen-dependent initially but can lose dependency and responsiveness. Tumor cells which are resistant to endocrine therapy ultimately proliferate. Androgen-independent or androgen-repressive cells can arise from androgen-sensitive prostate cancer cells by changes in specific gene expression over time in a clonal isolate. This change in androgen responsiveness was accompanied by a change in androgen receptor expression and transcriptional activity as well as expression of some oncogenes.<\/div><\/div><\/div>

<\/i><\/i><\/span>Study C - Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids.<\/span><\/a><\/h4><\/div>
STUDY C<\/strong>
\nInhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids.<\/p>\n

AUTHOR<\/strong>
\nLiang T; Liao S<\/p>\n

JOURNAL<\/strong>
\nJournal of Biochemistry, 1992 Jul 15, 285 ( Pt 2):, 557-62<\/p>\n

ABSTRACT<\/strong>
\nHuman or rat microsomal 5 alpha-reductase activity, as measured by enzymatic conversion of testosterone into 5 alpha-dihydrotestosterone or by binding of a competitive inhibitor, [3H]17 beta-NN-diethulcarbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one ([3H]4-MA) to the reductase, is inhibited by low concentrations (less than 10 microM) of certain polyunsaturated fatty acids. The relative inhibitory potencies of unsaturated fatty acids are, in decreasing order: gamma-linolenic acid greater than cis-4,7,10,13,16,19-docosahexaenoic acid = cis-6,9,12,15-octatetraenoic acid = arachidonic acid = alpha-linolenic acid greater than linoleic acid greater than palmitoleic acid greater than oleic acid greater than myristoleic acid. Other unsaturated fatty acids such as undecylenic acid, erucic acid and nervonic acid, are inactive. The methyl esters and alcohol analogues of these compounds, glycerols, phospholipids, saturated fatty acids, retinoids and carotenes were inactive even at 0.2 mM. The results of the binding assay and the enzymatic assay correlated well except for elaidic acid and linolelaidic acid, the trans isomers of oleic acid and linoleic acid respectively, which were much less active than their cis isomers in the binding assay but were as potent in the enzymatic assay. gamma-Linolenic acid had no effect on the activities of two other rat liver microsomal enzymes: NADH:menadione reductase and glucuronosyl transferase. gamma-Linolenic acid, the most potent inhibitor tested, decreased the Vmax. and increased Km values of substrates, NADPH and testosterone, and promoted dissociation of [3H]4-MA from the microsomal reductase. gamma-Linolenic acid, but not the corresponding saturated fatty acid (stearic acid), inhibited the 5 alpha-reductase activity, but not the 17 beta-dehydrogenase activity, of human prostate cancer cells in culture. These results suggest that unsaturated fatty acids may play an important role in regulating androgen action in target cells.<\/div><\/div><\/div><\/div><\/div>

<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>

AZELAIC ACID, VITAMIN B6 & ZINC<\/span><\/strong><\/h2><\/div>

This article published in British Journal of Dermatology demonstrated that when Azelaic acid, Zinc Sulfate and Vitamin B6 where combined at very low concentrations, a 90% inhibition of 5-Alpha Reductase was achieved.<\/p>\n<\/div>

<\/div><\/div><\/div>

<\/i><\/i><\/span>Study A - Inhibition of 5alpha-reductase activity in human skin by zinc and Azelaic acid.<\/span><\/a><\/h4><\/div>
STUDY A<\/strong>
\nInhibition of 5alpha-reductase activity in human skin by zinc and Azelaic acid.<\/p>\n

AUTHOR<\/strong>
\nStamatiadis, D; Bulteau-Portois, MC; Mowszowicz, I.<\/p>\n

JOURNAL<\/strong>
\nBritish Journal of Dermatology, 1988 Nov, 119(5):627-32.<\/p>\n

ABSTRACT<\/strong>
\nThe effects of zinc sulfate and azelaic acid on 5 alpha-reductase activity in human skin were studied using an in vitro assay with 1,2[3H]-testosterone as substrate. When added at concentrations of 3 or 9 mmol\/l, zinc was a potent inhibitor of 5-alpha-reductase activity. At high concentrations, zinc could completely inhibit the enzyme activity. Azelaic acid was also a potent inhibitor of 5 alpha-reductase; inhibition was detectable at concentrations as low as 0.2 mmol\/l and was complete at 3 mmol\/l. An additive effect of the two inhibitors was observed. Vitamin B6 potentiated the inhibitory effect of zinc, but not of azelaic acid, suggesting that two different mechanisms are involved. When the three substances were added together at very low concentrations which had shown to be ineffective alone, 90% inhibition of 5 alpha-reductase activity was obtained. If this inhibition is confirmed in vivo, zinc sulfate combined with azelaic acid could be an effective agent in the treatment of androgen related pathology of human skin.<\/div><\/div><\/div><\/div><\/div>

<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>

SAW PALMETTO<\/span><\/strong><\/h2><\/div>

In the following studies Saw Palmetto extract was shown to inhibit both type 1 and 2 forms of 5 alpha-reductase (Finasteride or Propecia\u00ae only inhibits type 2), was more potent than Finasteride and was able to effectively reduce binding of Testosterone and DHT to their receptors on various tissues. Please note that in the following studies Saw Palmetto Extract is referred to as Permixon or lipido-sterol extract of Serenoa repens (LSESr)<\/p>\n<\/div>

<\/div><\/div><\/div>

<\/i><\/i><\/span>Study A - Human prostatic steroid 5 alpha-reductase isoforms\u2013a comparative study of selective inhibitors.<\/span><\/a><\/h4><\/div>
STUDY A<\/strong>
\nHuman prostatic steroid 5 alpha-reductase isoforms\u2013a comparative study of selective inhibitors.<\/p>\n

This study suggests that Fenistride (active ingredient of Propecia) only inhibited the Type 2 form of 5 alpha reductase where Saw Palmetto extract inhibited both type 1 and 2 forms of 5 alpha-reductase and was more potent than Fenistride.<\/p>\n

AUTHOR<\/strong>
\nIehl\u00e9 C; D\u00e9los S; Guirou O; Tate R; Raynaud JP; Martin PM<\/p>\n

JOURNAL<\/strong>
\nJ Steroid Biochem Mol Biol, 54: 5-6, 1995 Sep, 273-9
\n
\nABSTRACT<\/strong>
\nThe present study describes the independent expression of the type 1 and 2 isoforms of human 5 alpha-reductase in the baculovirus-directed insect cell expression system and the selectivity of their inhibition. The catalytic properties and kinetic parameters of the recombinant isozymes were consistent with published data. The type 1 isoform displayed a neutral (range 6-8) pH optimum and the type 2 isoform an acidic (5-6) pH optimum. The type 2 isoform had higher affinity for testosterone than did the type 1 isoform (Km = 0.5 and 2.9 microM, respectively). Finasteride and turosteride were selective inhibitors of the type 2 isoform (Ki (type 2) = 7.3 and 21.7 nM compared to Ki (type 1) = 108 and 330 nM, respectively). 4-MA and the lipido-sterol extract of Serenoa repens (LSESr) markedly inhibited both isozymes (Ki (type 1) = 8.4 nM and 7.2 micrograms\/ml, respectively; Ki (type 2) = 7.4 nM and 4.9 micrograms\/ml, respectively). The three azasteroids were competitive inhibitors vs substrate, whereas LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme. These observations suggest that the lipid component of LSESr might be responsible for its inhibitory effect by modulating the membrane environment of 5 alpha-reductase. Partially purified recombinant 5 alpha-reductase type 1 activity was preserved by the presence of lipids indicating that lipids can exert either stimulatory or inhibitory effects on human 5 alpha-reductase.<\/div><\/div><\/div>

<\/i><\/i><\/span>Study B - Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts.<\/span><\/a><\/h4><\/div>
STUDY B<\/strong>
\nTestosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts.
\nThis Study shows that Fenistride and 4-MA inhibited the formation of some testostrone Metabolites (including DHT), where as Saw Palmetto inhibited the formation of all the Testostrone metabolites studied.<\/p>\n

AUTHOR<\/strong>
\nD\u00e9los S; Carsol JL; Ghazarossian E; Raynaud JP; Martin PM<\/p>\n

JOURNAL<\/strong>
\nJ Steroid Biochem Mol Biol, 55: 3-4, 1995 Dec, 375-83<\/p>\n

ABSTRACT<\/strong>
\nWe compare testosterone (T) metabolism in primary cultures of epithelial cells and fibroblasts separated from benign prostate hypertrophy (BPH) and prostate cancer tissues. In all cultures, androstenedione (delta 4) formed by oxidation of T by 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) represented 80% of the metabolites recovered. The amounts of 5 alpha-dihydrotestosterone (DHT), formed by reduction of T by 5 alpha-reductase (5 alpha-R), were small: 5 and 2% (BPH) and 8 and 15% (adenocarcinoma) for epithelial cells and fibroblasts, respectively. Northern blot analysis of total RNA from epithelial cells (BPH or adenocarcinoma) attributed the reductive activity to the 5 alpha-reductase type 1 isozyme and oxidative activity to the 17 beta-HSD type 2. In cancer fibroblasts, only little 17 beta-HSD type 2 mRNA was detected. The 5 alpha-reductase inhibitors, 4-MA (17 beta-(N,N-diethyl)carbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one) and finasteride, inhibited DHT formation with a preferential action of 4-MA on epithelial cells (BPH or adenocarcinoma) and of finasteride on fibroblasts from adenocarcinoma. Neither inhibitor acted on delta 4 formation. On the other hand, the lipido-sterol extract of Serenoa repens (LSESr, Permixon, Saw Palmetto) inhibited the formation of all the T metabolites studied [IC50 S = 40 and 200 micrograms\/ml (BPH) and 90 and 70 micrograms\/ml (adenocarcinoma) in epithelial cells and fibroblasts, respectively]. These results have important therapeutic implications when selecting appropriate treatment options for BPH.<\/div><\/div><\/div>

<\/i><\/i><\/span>Study C - The effect of Permixon on androgen receptors.<\/span><\/a><\/h4><\/div>
STUDY C<\/strong>
\nThe effect of Permixon on androgen receptors.
\nThis study shows that Saw Palmetto extract was able to effectively reduce Binding of Testostrone and DHT to their receptors on various tissues.<\/p>\n

AUTHOR<\/strong>
\nel-Sheikh MM; Dakkak MR; Saddique A<\/p>\n

JOURNAL<\/strong>
\nActa Obstet Gynecol Scand, 67: 5, 1988, 397-9<\/p>\n

ABSTRACT<\/strong>
\nPermixon, the liposterolic extract of the plant Serenoa Repens is a recently introduced drug for the treatment of benign prostatic hyperplasia. The effect of Permixon on dihydrotestosterone and testosterone binding by eleven different tissue specimens was tested. The drug reduced the mean uptake of both hormones by 40.9% and 41.9% respectively in all tissue specimens. Since hirsutism and virilism are among other gynecological problems caused either by excessive androgen stimulation or excess endorgan response, we suggest that Permixon could be a useful treatment in such conditions and recommend further investigations of the possible therapeutic values of the drug in gynecological practice.<\/div><\/div><\/div><\/div><\/div>

<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"yoast_head":"\nPublications - Revivogen MD<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/revivogen.ca\/md\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications - Revivogen MD\" \/>\n<meta property=\"og:url\" content=\"https:\/\/revivogen.ca\/md\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"Revivogen MD\" \/>\n<meta property=\"article:modified_time\" content=\"2016-11-17T03:19:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/revivogen.ca\/md\/publications\/\",\"url\":\"https:\/\/revivogen.ca\/md\/publications\/\",\"name\":\"Publications - Revivogen MD\",\"isPartOf\":{\"@id\":\"https:\/\/revivogen.ca\/md\/#website\"},\"datePublished\":\"2015-06-19T14:03:42+00:00\",\"dateModified\":\"2016-11-17T03:19:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/revivogen.ca\/md\/publications\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/revivogen.ca\/md\/publications\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/revivogen.ca\/md\/publications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/revivogen.ca\/md\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/revivogen.ca\/md\/#website\",\"url\":\"https:\/\/revivogen.ca\/md\/\",\"name\":\"Revivogen MD\",\"description\":\"A Natural Solution for Fine & Thinning Hair\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/revivogen.ca\/md\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-CA\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - Revivogen MD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/revivogen.ca\/md\/publications\/","og_locale":"en_US","og_type":"article","og_title":"Publications - Revivogen MD","og_url":"https:\/\/revivogen.ca\/md\/publications\/","og_site_name":"Revivogen MD","article_modified_time":"2016-11-17T03:19:52+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/revivogen.ca\/md\/publications\/","url":"https:\/\/revivogen.ca\/md\/publications\/","name":"Publications - Revivogen MD","isPartOf":{"@id":"https:\/\/revivogen.ca\/md\/#website"},"datePublished":"2015-06-19T14:03:42+00:00","dateModified":"2016-11-17T03:19:52+00:00","breadcrumb":{"@id":"https:\/\/revivogen.ca\/md\/publications\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/revivogen.ca\/md\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/revivogen.ca\/md\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/revivogen.ca\/md\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/revivogen.ca\/md\/#website","url":"https:\/\/revivogen.ca\/md\/","name":"Revivogen MD","description":"A Natural Solution for Fine & Thinning Hair","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/revivogen.ca\/md\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-CA"}]}},"_links":{"self":[{"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/pages\/11725"}],"collection":[{"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/comments?post=11725"}],"version-history":[{"count":1,"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/pages\/11725\/revisions"}],"predecessor-version":[{"id":12644,"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/pages\/11725\/revisions\/12644"}],"wp:attachment":[{"href":"https:\/\/revivogen.ca\/md\/wp-json\/wp\/v2\/media?parent=11725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}